Cited 5 times in

Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator

DC Field Value Language
dc.contributor.author송정식-
dc.contributor.author박용범-
dc.contributor.author이상원-
dc.date.accessioned2020-10-04T16:46:44Z-
dc.date.available2020-10-04T16:46:44Z-
dc.date.issued2020-08-
dc.identifier.issn0513-5796-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/179662-
dc.description.abstractPurpose: There has been no extensive study to compare the efficacy between rituximab originator (Mabthera®) and its biosimilar (Truxima®) for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Here, we investigated the clinical effects of rituximab on poor outcomes of MPA and GPA in Korean patients, and compared those between Mabthera® and Truxima®. Materials and methods: We retrospectively reviewed the medical records of a total of 139 patients, including 97 MPA patients and 42 GPA patients. At diagnosis, antineutrophil cytoplasmic antibody positivity and comorbidities were assessed. During follow-up, all-cause mortality, relapse, end-stage renal disease, cerebrovascular accident and acute coronary syndrome were evaluated as poor outcomes. In this study, rituximab was used as either Mabthera® or Truxima®. Results: The median age at diagnosis was 60.1 years and 46 patients were men (97 MPA and 42 GPA patients). Among poor outcomes, patients receiving rituximab exhibited a significantly lower cumulative relapse-free survival rate compared to those not receiving rituximab (p=0.002). Nevertheless, rituximab use did not make any difference in other poor outcomes of MPA and GPA except for relapse, which might be a rebuttal to the fact that rituximab use after relapse eventually led to better prognosis. There were no significant differences in variables at diagnosis and during follow-up between patients receiving Mabthera® and those receiving Truxima®. Patients receiving Truxima® exhibited a similar pattern of the cumulative survival rates of each poor outcome to those receiving Mabthera®. Conclusion: Truxima® prevents poor outcomes of MPA and GPA as effectively as does Mabthera®.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherYonsei University-
dc.relation.isPartOfYONSEI MEDICAL JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHBiosimilar Pharmaceuticals / therapeutic use*-
dc.subject.MESHFemale-
dc.subject.MESHGranulomatosis with Polyangiitis / drug therapy*-
dc.subject.MESHGranulomatosis with Polyangiitis / mortality-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMicroscopic Polyangiitis / drug therapy*-
dc.subject.MESHMicroscopic Polyangiitis / mortality-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPrognosis-
dc.subject.MESHRecurrence-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRituximab / therapeutic use*-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTreatment Outcome-
dc.titleRituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorHyeok Chan Kwon-
dc.contributor.googleauthorMinyoung Kevin Kim-
dc.contributor.googleauthorJason Jungsik Song-
dc.contributor.googleauthorYong Beom Park-
dc.contributor.googleauthorSang Won Lee-
dc.identifier.doi10.3349/ymj.2020.61.8.712-
dc.contributor.localIdA02057-
dc.contributor.localIdA01579-
dc.contributor.localIdA02824-
dc.relation.journalcodeJ02813-
dc.identifier.eissn1976-2437-
dc.identifier.pmid32734735-
dc.subject.keywordRituximab-
dc.subject.keywordbiosimilar-
dc.subject.keywordgranulomatosis with polyangiitis-
dc.subject.keywordmicroscopic polyangiitis-
dc.subject.keywordprognosis-
dc.contributor.alternativeNameSong, Jason Jungsik-
dc.contributor.affiliatedAuthor송정식-
dc.contributor.affiliatedAuthor박용범-
dc.contributor.affiliatedAuthor이상원-
dc.citation.volume61-
dc.citation.number8-
dc.citation.startPage712-
dc.citation.endPage719-
dc.identifier.bibliographicCitationYONSEI MEDICAL JOURNAL, Vol.61(8) : 712-719, 2020-08-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.